Table 2.
Expressions of VEGFs and their receptors in primary ovarian carcinomas and related metastases
| Variable | Primary tumor (n = 86) | Metastases (n = 16) | p | Variable | Primary tumor (n = 85) | Metastases (n = 16) | p |
|---|---|---|---|---|---|---|---|
| VEGF-A | VEGFR1 | ||||||
| IRS | 6 | 10.5 | ns | IRS | 6 | 7 | ns |
| PP | 70 | 85 | 0.022 | PP | 80 | 80 | ns |
| SI | ns | SI | 0.046 | ||||
| 0 or weak | 13 (15%) | 2 (13%) | Weak | 18 (21%) | 2 (12%) | ||
| Moderate | 45 (52%) | 5 (31%) | Moderate | 39 (46%) | 8 (50%) | ||
| Strong | 28 (33%) | 9 (56%) | Strong | 28 (33%) | 6 (38%) | ||
| Stroma SI | Stroma SI | ||||||
| Weak | 51 (59%) | 7 (44%) | Weak | 47 (55%) | 4 (25%) | ||
| Strong | 35 (41%) | 9 (56%) | Strong | 38 (45%) | 12 (75%) | ||
| VEGF-D | VEGFR2 | ||||||
| IRS | 4 | 7 | 0.013 | IRS | 3 | 2 | ns |
| PP | 60 | 90 | 0.010 | PP | 60 | 40 | ns |
| SI | ns | SI | ns | ||||
| 0 or weak | 35 (41%) | 4 (25%) | 0 or weak | 50 (59%) | 12 (75%) | ||
| Moderate | 37 (43%) | 7 (44%) | Moderate | 29 (34%) | 4 (25%) | ||
| Strong | 14 (16%) | 5 (31%) | Strong | 6 (7%) | 0 | ||
| Stroma SI | Stroma SI | ||||||
| Weak | 66 (77%) | 7 (44%) | Weak | 46 (54%) | 4 (25%) | ||
| Strong | 20 (23%) | 9 (56%) | Strong | 39 (46%) | 12 (75%) | ||
| VEGF-C | VEGFR3 | ||||||
| IRS | 8 | 9 | ns | IRS | 6 | 6 | ns |
| PP | 80 | 70 | 0.010 | PP | 60 | 65 | ns |
| SI | ns | SI | ns | ||||
| Weak | 8 (9%) | 2 (13%) | Weak | 36 (42%) | 3 (19%) | ||
| Moderate | 46 (54%) | 4 (25%) | Moderate | 40 (47%) | 9 (56%) | ||
| Strong | 31 (36%) | 10 (62%) | Strong | 9 (11%) | 4 (25%) | ||
| Stroma SI | Stroma SI | ||||||
| Weak | 45 (53%) | 11 (69%) | Weak | 35 (41%) | 3 (19%) | ||
| Strong | 40 (47%) | 5 (31%) | Strong | 50 (59%) | 13 (81%) | ||
IRS and PP are presented as median values, SI is presented as n (%)
IRS immunoreactive score, PP percentage of positively stained epithelial cells, SI staining intensity